The Journal for ImmunoTherapy of Cancer (JITC) is the official journal of the Society for Immunotherapy of Cancer (SITC). This open access, peer-reviewed journal not only serves as the global voice of the society, but also a targeted outlet for the publication of original research articles, literature reviews, position papers and discussion on all aspects of tumor immunology and cancer immunotherapy–from basic research to clinical application.
Today, more than ever before, the tremendous excitement in the field and the increased momentum brought about by the latest approvals of immunotherapy-based treatments in various cancer types has shown the clear need for JITC, an outlet devoted to and created by today's leaders in the field.
Read the Journal for ImmunoTherapy of Cancer (JITC)
As of October 10, 2019, JITC has transitioned to ScholarOne for all new manuscripts. If you have any questions regarding submission to the new peer review system, or require assistance submitting your manuscript, please contact the Editorial Assistant (firstname.lastname@example.org).
If you are interested in submitting a revision for a paper previously submitted in the former system, please contact Michelle.FengHe@biomedcentral.com for assistance.
JITC will be launching two new sections at the beginning of 2020 and is now collecting submissions for peer review. Read more about these sections, "Immune Cell Therapies and Immune Cell Engineering" and "Oncolytic and Local Immunotherapy", and submit today!
Pedro J. Romero, MD, JITC Editor-in-Chief, welcomes applications from interested individuals who would like to take advantage of the many benefits of serving as a JITC manuscript reviewer. Benefits include:
The Journal for ImmunoTherapy of Cancer (JITC) increased its impact factor to 8.728 in 2019. JITC’s impact factor places JITC in the top 3 percent of all fully open access oncology journals and ranks it in the top 8 percent of all journals published in the categories of oncology and immunology.
Published in the annual Journal Citation Reports (JCR), the latest JITC impact factor is a calculation determined on the number of 2018 citations accumulated for JITC manuscripts published in 2016 and 2017. Other journal metrics for JITC may be found on the journal website.
As a way to thank the SITC members who work tirelessly to advance the science and improve the lives of cancer patients, SITC will provide members with a 60 percent discount on processing fees for all JITC articles submitted and accepted in 2019. For questions regarding the discount that would be verified and applied upon post-review acceptance, please contact JITCEditor@sitcancer.org or (414) 271-2456.
Basic Tumor Immunology
Clinical Trials Monitor
Clinical/Translational Cancer Immunotherapy
Guidelines and Consensus Statements
Indicated below by a circular image near the author listings, the Altmetric Attention Score for research outputs provides an indicator of the amount of attention an article has received. The score is derived from an automated algorithm and represents a weighted count of the amount of attention picked up for a research output. Learn more here.
Blocking programmed death-1 (PD-1) is considered to be a promising strategy to improve T cell function, and this is being explored in many ongoing clinical trials. In fact, our knowledge about PD-1 is primarily based on the results of short-term experiments or observations, but how long-lasting PD-1 blockade can affect T cell function remains unclear.
Immunotherapy has led to a paradigm shift in the treatment of many advanced malignancies. Despite the success in treatment of tumors like non-small cell lung cancer (NSCLC) and melanoma, checkpoint inhibition-based immunotherapy has limitations. Many tumors, such as pancreatic cancer, are less responsive to checkpoint inhibitors, where patients tend to have a limited duration of benefit and where clinical responses are more robust in patients who are positive for predictive biomarkers. One of the critical factors that influence the efficacy of immunotherapy is the tumor microenvironment (TME), which contains a heterogeneous composition of immunosuppressive cells.
Dear All, I'll be attending SITC 2019 on November 7-8 and would like to network with anyone interested in or studying these topics. I'm new to the field of IO therapy and would appreciate any help making connections. Thanks, Rick ------------------------------ ...
Princeton Center for Theoretical Science presents the 2019 Distinguished Visiting Lecturer
Laboratoire de Physique Théorique Ecole Normale Supérieure Public Lecture : "The Evolution Within Us: Statistics of Immunity" ...
2019 Annual Cancer Treatment-Related Adverse Events Symposium
Friday-Saturday, October 25-26, 2019 Memorial Sloan Kettering Cancer Center Register online: http://www.mskcc.org/AdverseEvents
Systemic anticancer therapies (cytotoxic ...
I would like to personally invite you to join Kim Margolin, MD, Ahmad Tahini, MD, PhD, and myself for SITC Webinar: I-O Highlights from ASCO 2019 , a free SITC webinar on Aug. 28 at Noon EDT where we discuss the latest advances ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com